Zai Lab Ltd stock analysis
Zai Lab Ltd (1ZLB) Stock Price & Analysis
1ZLB Stock Chart & Stats
- Day’s Range
- EUR 2.20 - EUR 2.38
- 52-Week Range
- EUR 1.26 - EUR 2.42
- Previous Close
- EUR 2.34
- Volume
- N/A
- Average Volume (3M)
- 299
- Market Cap
- EUR 2.96B
- Enterprise Value
- EUR 20.11B
- Total Cash (Recent Filing)
- EUR 559.66M
- Total Debt (Recent Filing)
- EUR 267.45M
- Price to Earnings (P/E)
- ―
- Beta
- 0.89
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- -0.05
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Diversified Biotech Platform
Zai Lab has exposure to several therapeutic areas and combines in-licensed assets with internally developed candidates and commercial medicines. This diversified model can spread development risk, support multiple growth avenues, and sustain a broader long-term opportunity set.
Healthy Gross Margin
A gross margin of about 56% indicates that commercial products retain meaningful economic value after direct costs. If maintained as the portfolio scales, this provides a foundation for funding selling, research, and development expenses while supporting eventual operating leverage.
Broader Reimbursement Access
The 2026 NRDL additions expand reimbursement-supported access for key medicines in myasthenia gravis and schizophrenia, while renewals preserve oncology and infectious-disease coverage. This strengthens the portfolio’s commercial reach and supports more durable patient access in China.
Bears Say
Persistent Unprofitability
Zai Lab remains materially unprofitable despite a healthy gross margin and improvement from earlier losses. Continued operating and net losses limit internally funded expansion, require sustained investment to reach scale, and leave the company without a demonstrated path to consistent break-even.
Ongoing Cash Consumption
Persistent operating and free-cash-flow deficits show that the business is still consuming cash to run and develop its operations. Continued burn increases reliance on capital raises or additional debt, potentially constraining investment choices and diluting financial flexibility.
TTM Revenue Reversal
The sharp TTM revenue reversal interrupts the company’s earlier scaling trend and raises concern about the durability of commercial momentum. Weaker top-line performance can reduce operating leverage, make fixed development spending harder to absorb, and delay progress toward profitability.
1ZLB FAQ
What was Zai Lab Ltd’s price range in the past 12 months?
What is Zai Lab Ltd’s market cap?
When is Zai Lab Ltd’s upcoming earnings report date?
How were Zai Lab Ltd’s earnings last quarter?
Is Zai Lab Ltd overvalued?
Does Zai Lab Ltd pay dividends?
What is Zai Lab Ltd’s EPS estimate?
How many shares outstanding does Zai Lab Ltd have?
What happened to Zai Lab Ltd’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Zai Lab Ltd?
What is the TipRanks Smart Score and how is it calculated?
Zai Lab Ltd Stock Smart Score
Company Description
Zai Lab Ltd
Zai Lab Limited, established in 2013 and based in Shanghai, China, is a biopharmaceutical company dedicated to developing and bringing to market innovative medical treatments. Its core focus spans oncology, autoimmune diseases, infectious diseases, and neurological conditions, primarily serving patients in Mainland China and Hong Kong. The company's portfolio of commercialized products includes Zejula, an oral, once-daily poly polymerase 1/2 inhibitor; Optune, a non-invasive device employing tumor treating fields; NUZYRA for addressing acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Zai Lab also maintains a robust pipeline of investigational therapies. This pipeline features numerous oncology assets such as Odronextamab for various lymphomas, Repotrectinib—a tyrosine kinase inhibitor targeting ROS1 and TRK fusions, Margetuximab for breast and gastroesophageal cancers, Adagrasib for KRAS-G12C-mutated solid tumors, and Bemarituzumab for gastric and gastroesophageal junction cancers. Other notable pipeline candidates include CLN-081 for specific non-small cell lung cancers, multi-targeted kinase inhibitors like Elzovantinib, several monoclonal antibodies (e.g., Tebotelimab, Retifanlimab, ZL-1201), and immune modulators such as Efgartigimod for reducing disease-causing IgG antibodies and ZL-1102 targeting IL-17A. Additionally, the company is advancing therapies like KarXT for psychiatric and neurological disorders, novel EGFR inhibitors (ZL-2313, ZL-2314), a CDC7 kinase inhibitor (ZL-2309), and Sulbactam/durlobactam for serious Acinetobacter infections, showcasing its commitment to a broad range of therapeutic innovations.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ying Du
- Employees
- 1,784
- Website
- www.zailaboratory.com
- Address
- Jinchuang Plaza, Shanghai, SH, 201210, CN
Zai Lab Ltd (1ZLB) Earnings & Revenues
1ZLB Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 1 | 5 |
| Technical Analysis | 5 | 1 | 4 |
| Moving Averages | 11 | 0 | 1 |
